Andrew Feinberg is the Chairman and CEO of Netcracker Technology, an industry leader offering mission-critical solutions to communications service providers worldwide. Netcracker’s comprehensive portfolio of software and professional services enables large-scale digital transformations, unlocking the opportunities of the cloud, virtualization and the changing mobile ecosystem. Feinberg guided the company through a sustained period of consistent market share gains and profitable double-digit revenue growth, leading to Netcracker’s successful acquisition by NEC in 2008. Since then, he has taken a global leadership role for NEC, including responsibility for a multibillion-dollar services and software expansion comprising significant advances in BSS, OSS, cloud, virtualization and 5G technologies. Feinberg serves on Netcracker's Executive Committee and is the Chairman of the Board of Directors.
In addition, Feinberg is the Chairman, CEO and President of BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients. Since founding the company in 2015, Feinberg has established BostonGene as a market leader by integrating molecular and immune science with biomedical software, artificial intelligence and machine learning to develop and deliver clinically applicable innovative solutions to fight cancer that have saved countless lives. Feinberg’s leadership has led BostonGene to partner with leading cancer centers around the world, collaborate with physicians and scientists on hundreds of research projects, secure more than 100 patents, and publish over 100 landmark publications demonstrating the clinical utility of BostonGene‘s deep molecular and immune profiling and analytics to advance precision medicine for cancer patients.
He holds an MBA from the Wharton School of the University of Pennsylvania and a B.S. from Bentley University.